Royalty Pharma Acquires $100M Stake in Rusfertide for Polycythemia Vera
On August 12, Royalty Pharma (NASDAQ:RPRX) agreed to pay Zealand Pharma $100 million for future royalties on rusfertide, an experimental treatment for the rare blood disorder polycythemia vera. The deal includes a $50 million upfront payment and another $50 million due one year later in exchange for a 1% royalty on global sales plus regulatory and commercial milestones. Rusfertide is currently awaiting FDA approval with a decision expected by Q3 2026, making it an immediate catalyst for the company. Royalty Pharma's second-quarter 2026 results showed strong performance from its broader portfolio, including $768 million in royalty receipts and updated full-year guidance of $3.4 billion to $3.5 billion. The firm has deployed over $1 billion in capital this year alone, with a focus on development-stage therapies like AstraZeneca's cliramitug. However, the company faces risks from declining royalties due to generic competition and patent expirations, as seen with Promacta and Imbruvica. The rusfertide deal also caps Royalty Pharma’s royalty at 0.75% once global sales exceed $1.5 billion.
Topics: blood disorder treatment FDA approval pharmaceuticals royalty deals